At present, the company has eight drugs including didanosine, stavudine, nevirapine, zidovudine, indinavir, efavirenz, nelfinavir and lamivudine. APIs can be produced and exported, and we are the only company in China that specializes in the production of raw materials for such pharmaceuticals. In 2001, the company's first AIDS treatment drug, Didanosine (DDI), submitted a clinical research application to the National Medical Products Administration. This was also the first chemically synthesized AIDS drug in my country to apply to the National Medical Products Administration. At present, the company has obtained new drug certificates and production approvals for three AIDS treatment drugs including didanosine (DDI), stavudine (D4T) and nevirapine (NVP). The fourth AIDS treatment drug zidovudine (AZT) It has also obtained a new drug certificate. The company's APIs are all exported and enjoy high reputation and market share in the international market.
Anti-tumor APIs are another important product series of the company, with semi-synthetic paclitaxel and docetaxel as the main varieties. Among them, the semi-synthetic method of producing paclitaxel is a Shanghai high-tech achievement transformation project; the semi-synthetic method of producing docetaxel, Desano Company, is the largest and most technologically mature manufacturer in China, and has applied for a patent. Since the start of production in 2000, the products have been exported to Europe, South America and Southeast Asia, with stable quality and well received by customers.
As a key industrial field for future development, the company will actively cooperate with the national AIDS prevention and treatment plan through various channels, participate in and promote the development of China's AIDS prevention and treatment cause, and increase the development of anti-tumor drugs. It plans to expand production varieties and scale, actively develop new drugs with independent intellectual property rights, and strive to develop into a major domestic and foreign manufacturer of antiviral APIs and anti-tumor APIs within three years.